Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2013

01.12.2013 | Translational Research and Biomarkers

Frequent Alterations of MCPH1 and ATM are Associated with Primary Breast Carcinoma: Clinical and Prognostic Implications

verfasst von: Nilanjana Bhattacharya, PhD, Nupur Mukherjee, MSc, Ratnesh K. Singh, PhD, Satyabrata Sinha, PhD, Neyaz Alam, MS, Anup Roy, MD, Susanta Roychoudhury, PhD, Chinmay Kumar Panda, PhD

Erschienen in: Annals of Surgical Oncology | Sonderheft 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

MCPH1 is a proximal regulator of DNA damage response pathway that is involved in recruitment of phosphorylated ATM to double-stranded DNA breaks.

Methods

To understand the importance of MCPH1 and ATM in deregulation of DNA damage response pathway in breast carcinoma, we studied m-RNA expression and genetic/epigenetic alterations of these genes in primary breast carcinoma samples.

Results

Our study revealed reduced expression (mRNA/protein) and high alterations (deletion/methylation) (96 %, 121 of 126) of MCPH1 and ATM. Mutation was, however, rare in inactivation of MCPH1. In immunohistochemical analysis, reduced protein expression of MCPH1, ATM and p-ATM were concordant with their molecular alterations (P = 0.03–0.01). Alterations of MCPH1 and deletion of ATM were significantly high in estrogen/progesterone receptor–negative than estrogen/progesterone receptor–positive breast carcinoma samples compared to early or late age of onset tumors, indicating differences in pathogenesis of the molecular subtypes (P = 0.004–0.01). These genes also showed differential association with tumor stage, grade and lymph node status in different subtypes of breast carcinoma (P = 0.00001–0.01). Their coalterations showed significant association with tumor progression and prognosis (P = 0.003–0.05). Interestingly, patients with alterations of these genes or MCPH1 alone had poor outcome after treatment with DNA-interacting drugs and/or radiation (P = 0.01–0.05).

Conclusions

Inactivation of MCPH1-ATM-associated DNA damage response pathway might have an important role in the development of breast carcinoma with diagnostic, prognostic and therapeutic implications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
2.
Zurück zum Zitat Sen U, Sankaranarayanan R, Mandal S, et al. Cancer patterns in eastern India: the first report of the Kolkata cancer registry. Int J Cancer. 2002;100:86–91.CrossRefPubMed Sen U, Sankaranarayanan R, Mandal S, et al. Cancer patterns in eastern India: the first report of the Kolkata cancer registry. Int J Cancer. 2002;100:86–91.CrossRefPubMed
3.
Zurück zum Zitat Ellsworth RE, Decewicz DJ, Shriver CD. Breast cancer in the personal genomics era. Curr Genomics. 2010;11:146–61.CrossRefPubMed Ellsworth RE, Decewicz DJ, Shriver CD. Breast cancer in the personal genomics era. Curr Genomics. 2010;11:146–61.CrossRefPubMed
4.
Zurück zum Zitat Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17:R245–62.CrossRefPubMed Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17:R245–62.CrossRefPubMed
5.
Zurück zum Zitat Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr. 1994;16:35–42.PubMed Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr. 1994;16:35–42.PubMed
6.
Zurück zum Zitat Sinha S, Chunder N, Mukherjee N, et al. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma. Ann Surg Oncol. 2008;15:1070–80.CrossRefPubMed Sinha S, Chunder N, Mukherjee N, et al. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma. Ann Surg Oncol. 2008;15:1070–80.CrossRefPubMed
7.
Zurück zum Zitat Xu K, Cui J, Olman V, et al. A comparative analysis of gene-expression data of multiple cancer types. Plos One. 2010;5:e13696.CrossRefPubMed Xu K, Cui J, Olman V, et al. A comparative analysis of gene-expression data of multiple cancer types. Plos One. 2010;5:e13696.CrossRefPubMed
8.
Zurück zum Zitat Lin SH, Liang Y, Li K. Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression. Yonsei Med J. 2010;51:295–301.CrossRefPubMed Lin SH, Liang Y, Li K. Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression. Yonsei Med J. 2010;51:295–301.CrossRefPubMed
9.
Zurück zum Zitat Chaplet M, Rai R, Jackson-Bernitsas D, et al. BRIT1/MCPH1: a guardian of genome and an enemy of tumors. Cell Cycle. 2006;5:2579–83.CrossRefPubMed Chaplet M, Rai R, Jackson-Bernitsas D, et al. BRIT1/MCPH1: a guardian of genome and an enemy of tumors. Cell Cycle. 2006;5:2579–83.CrossRefPubMed
10.
Zurück zum Zitat Rai R, Dai H, Multani AS, et al. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell. 2006;10:145–57.CrossRefPubMed Rai R, Dai H, Multani AS, et al. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell. 2006;10:145–57.CrossRefPubMed
11.
Zurück zum Zitat Liang Y, Gao H, Lin SY, et al. BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet. 2010;6:e1000826.CrossRefPubMed Liang Y, Gao H, Lin SY, et al. BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet. 2010;6:e1000826.CrossRefPubMed
12.
Zurück zum Zitat Bhattacharya N, Chunder N, Basu D, et al. Three discrete areas within the chromosomal 8p21.3–23 region are associated with the development of breast carcinoma of Indian patients. Exp Mol Pathol. 2004;76:264–71.CrossRefPubMed Bhattacharya N, Chunder N, Basu D, et al. Three discrete areas within the chromosomal 8p21.3–23 region are associated with the development of breast carcinoma of Indian patients. Exp Mol Pathol. 2004;76:264–71.CrossRefPubMed
13.
Zurück zum Zitat Radford DM, Fair KL, Phillips NJ, et al. Allelotyping of ductal carcinoma in situ (DCIS) of the breast; deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res. 1995;55:3399–405.PubMed Radford DM, Fair KL, Phillips NJ, et al. Allelotyping of ductal carcinoma in situ (DCIS) of the breast; deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res. 1995;55:3399–405.PubMed
14.
Zurück zum Zitat Wistuba BC, Virmani AK, Milchgrub S, et al. Allelic losses at chromosome 8p21–23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999;59:1973–9.PubMed Wistuba BC, Virmani AK, Milchgrub S, et al. Allelic losses at chromosome 8p21–23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999;59:1973–9.PubMed
15.
Zurück zum Zitat Trimborn M, Bell SM, Felix C, et al. Mutations in microcephalin cause aberrant regulation of chromosome condensation. Am J Hum Genet. 2004;75:261–6.CrossRefPubMed Trimborn M, Bell SM, Felix C, et al. Mutations in microcephalin cause aberrant regulation of chromosome condensation. Am J Hum Genet. 2004;75:261–6.CrossRefPubMed
16.
Zurück zum Zitat Richardson J, Shaaban AM, Kamal M, et al. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat. 2011;127:639–48.CrossRefPubMed Richardson J, Shaaban AM, Kamal M, et al. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat. 2011;127:639–48.CrossRefPubMed
17.
Zurück zum Zitat Chunder N, Mandal S, Roy A, et al. Differential association of BRCA1 and BRCA2 genes with some breast cancer–associated genes in early and late onset breast tumors. Ann Surg Oncol. 2004;11:1045–55.CrossRefPubMed Chunder N, Mandal S, Roy A, et al. Differential association of BRCA1 and BRCA2 genes with some breast cancer–associated genes in early and late onset breast tumors. Ann Surg Oncol. 2004;11:1045–55.CrossRefPubMed
18.
Zurück zum Zitat Ding SL, Sheu LF, Yu JC, et al. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer. 2004;90:1995–2001.CrossRefPubMed Ding SL, Sheu LF, Yu JC, et al. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer. 2004;90:1995–2001.CrossRefPubMed
19.
Zurück zum Zitat Prokopcova J, Kleibl Z, Banwell MC, et al. The role of ATM in breast cancer development. Cancer Res Treat. 2007;104:121–8.CrossRef Prokopcova J, Kleibl Z, Banwell MC, et al. The role of ATM in breast cancer development. Cancer Res Treat. 2007;104:121–8.CrossRef
20.
Zurück zum Zitat Treilleux I, Chapot B, Goddard S, et al. The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology. 2007;51:63–9.CrossRefPubMed Treilleux I, Chapot B, Goddard S, et al. The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology. 2007;51:63–9.CrossRefPubMed
21.
Zurück zum Zitat Ye C, Cai Q, Dai Q, et al. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer. 2007;109:1729–35.CrossRefPubMed Ye C, Cai Q, Dai Q, et al. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer. 2007;109:1729–35.CrossRefPubMed
22.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) method. Methods. 2001;25:402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) method. Methods. 2001;25:402–8.CrossRefPubMed
23.
Zurück zum Zitat Dasgupta S, Mukherjee N, Roy S, et al. Mapping of candidate tumor suppressor genes’ loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. Oral Oncol. 2002;38:6–15.CrossRefPubMed Dasgupta S, Mukherjee N, Roy S, et al. Mapping of candidate tumor suppressor genes’ loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. Oral Oncol. 2002;38:6–15.CrossRefPubMed
24.
Zurück zum Zitat Ivanova T, Petrenko A, Gritsko T, et al. Methylation and silencing of the retinoic acid receptor-b2 gene in cervical cancer. BMC Cancer. 2002;2:4.CrossRefPubMed Ivanova T, Petrenko A, Gritsko T, et al. Methylation and silencing of the retinoic acid receptor-b2 gene in cervical cancer. BMC Cancer. 2002;2:4.CrossRefPubMed
25.
Zurück zum Zitat Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.CrossRefPubMed Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.CrossRefPubMed
26.
Zurück zum Zitat Tripathi Bhar A, Banerjee S, Chunder N, et al. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol. 2003;129:642–50. Tripathi Bhar A, Banerjee S, Chunder N, et al. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Can Res Clin Oncol. 2003;129:642–50.
27.
Zurück zum Zitat Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2006;12:6643–51.CrossRefPubMed Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2006;12:6643–51.CrossRefPubMed
28.
Zurück zum Zitat Mitra S, Mazumder (Indra) D, Bhattacharya N, et al. RBSP3 is frequently altered in premalignant cervical lesions: clinical and prognostic significance. Gene Chromosome Cancer. 2010;49:155–70. Mitra S, Mazumder (Indra) D, Bhattacharya N, et al. RBSP3 is frequently altered in premalignant cervical lesions: clinical and prognostic significance. Gene Chromosome Cancer. 2010;49:155–70.
29.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMed Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMed
30.
Zurück zum Zitat Knudson AG. Genetics and etiology of human cancer. Adv Hum Genet. 1977;8:1–66.PubMed Knudson AG. Genetics and etiology of human cancer. Adv Hum Genet. 1977;8:1–66.PubMed
31.
Zurück zum Zitat Dey S, Boffetta P, Mathews A, et al. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer. 2009;125:1663–70.CrossRefPubMed Dey S, Boffetta P, Mathews A, et al. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer. 2009;125:1663–70.CrossRefPubMed
32.
Zurück zum Zitat Kakarala M, Rozek L, Cote M, et al. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US—a SEER analysis. BMC Cancer. 2010;10:191.CrossRefPubMed Kakarala M, Rozek L, Cote M, et al. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US—a SEER analysis. BMC Cancer. 2010;10:191.CrossRefPubMed
33.
Zurück zum Zitat Vo QN, Kim WJ, Cvitanovic L, et al. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene. 2004;23:9432–7.CrossRefPubMed Vo QN, Kim WJ, Cvitanovic L, et al. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene. 2004;23:9432–7.CrossRefPubMed
34.
Zurück zum Zitat Brandes JC, Carraway H, Herman JG, et al. Optimal primer design using the novel primer design program: MSP primer provides accurate methylation analysis of the ATM promoter. Oncogene. 2007;26:6229–37.CrossRefPubMed Brandes JC, Carraway H, Herman JG, et al. Optimal primer design using the novel primer design program: MSP primer provides accurate methylation analysis of the ATM promoter. Oncogene. 2007;26:6229–37.CrossRefPubMed
35.
Zurück zum Zitat Bilbao C, Ramírez R, Rodríguez G, et al. Double strand break repair components are frequent targets of microsatellite instability in endometrial cancer. Eur J Cancer. 2010;46:2821–7.CrossRefPubMed Bilbao C, Ramírez R, Rodríguez G, et al. Double strand break repair components are frequent targets of microsatellite instability in endometrial cancer. Eur J Cancer. 2010;46:2821–7.CrossRefPubMed
36.
Zurück zum Zitat Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of “conditional haploinsufficiency.” Cell Cycle. 2007;6:2344–7.CrossRefPubMed Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of “conditional haploinsufficiency.” Cell Cycle. 2007;6:2344–7.CrossRefPubMed
37.
Zurück zum Zitat Rai R, Phadnis A, Haralkar S, et al. Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle. 2008;7:2225–33.CrossRefPubMed Rai R, Phadnis A, Haralkar S, et al. Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle. 2008;7:2225–33.CrossRefPubMed
38.
Zurück zum Zitat Tommiska J, Bartkova J, Heinonen M, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27:2501–6.CrossRefPubMed Tommiska J, Bartkova J, Heinonen M, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27:2501–6.CrossRefPubMed
39.
Zurück zum Zitat Angèle S, Treilleux I, Tanière P, et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res. 2000;6:3536–44.PubMed Angèle S, Treilleux I, Tanière P, et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res. 2000;6:3536–44.PubMed
40.
Zurück zum Zitat Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 2000;60:3884–92.PubMed Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 2000;60:3884–92.PubMed
41.
Zurück zum Zitat Bozhanov SS, Angelova SG, Krasteva ME, et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol. 2010;136:1657–69.CrossRefPubMed Bozhanov SS, Angelova SG, Krasteva ME, et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol. 2010;136:1657–69.CrossRefPubMed
Metadaten
Titel
Frequent Alterations of MCPH1 and ATM are Associated with Primary Breast Carcinoma: Clinical and Prognostic Implications
verfasst von
Nilanjana Bhattacharya, PhD
Nupur Mukherjee, MSc
Ratnesh K. Singh, PhD
Satyabrata Sinha, PhD
Neyaz Alam, MS
Anup Roy, MD
Susanta Roychoudhury, PhD
Chinmay Kumar Panda, PhD
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe Sonderheft 3/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2715-6

Weitere Artikel der Sonderheft 3/2013

Annals of Surgical Oncology 3/2013 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.